KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors
Abstract KRAS mutations are broadly recognized as promising targets for tumor therapy.T cell receptors (TCRs) can specifically recognize KRAS mutant neoantigens presented by human lymphocyte antigen (HLA) and mediate T cell responses to eliminate tumor cells.In the present study, we identify two TCRs specific stagg sdm70 for the 9-mer KRAS-G12V mut